ERBB2 and neoplasm: Ineligible patients were more likely to have a higher grade (p = 0.007), higher TNM stage (p < 0.001), HER-2-negative (p = 0.004), higher Ki67 index (p = 0.001), larger tumor size (p = 0.001), more diffuse micro-calcification (p = 0.001), and were more likely to receive AC plus paclitaxel only (p = 0.008).